albuterol (Armstrong Albuterol HFA) vs fenoterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline

albuterol (Armstrong Albuterol HFA)

Marketed by Amphastar Pharmaceuticals, Inc.

Approved in Asthmasmall molecule
Partial signal

NCT00634829 · Phase 3 · terminated

This is a randomized, quadruple-blind, placebo- and active-controlled crossover study measuring lung function directly, but the sample size is small and no results have been posted yet, so the outcome remains unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Next expected readout: April 2028 · NCT07426458 (registry estimate)

No aligned efficacy figure on record for this race.

fenoterol

Marketed by Boehringer Ingelheim

Phase 3 in Asthmasmall molecule
Partial signal

NCT02177370 · Phase 3 · terminated

This was a randomized, double-blind, active-controlled crossover study, but it enrolled only 19 participants and one of its two primary measures is a laboratory receptor-density biomarker rather than a direct asthma outcome, and no results have been posted.

No aligned efficacy figure on record for this race.

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointalbuterol (Armstrong Albuterol HFA)fenoterol
Severe exacerbations, annualised rate—Not posted · NCT00667407—Not reported
Trough FEV1, change—Not posted · NCT00667407—Not reported
ACQ-5, change—Not posted · NCT00667407—Not reported
OCS dose reduction—Not posted · NCT00667407—Not reported

Severe exacerbations, annualised rate

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
fenoterol
—Not reported

Trough FEV1, change

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
fenoterol
—Not reported

ACQ-5, change

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
fenoterol
—Not reported

OCS dose reduction

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
fenoterol
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

albuterol (Armstrong Albuterol HFA): registry results are on file for Asthma, but their comparison mappings are not yet available.

fenoterol: no structured comparison results are available for Asthma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Armstrong Albuterol HFA)'s landscape · fenoterol's landscape